Immunotherapy of immunosenesence; who, how and when?
| dc.contributor.author | Govind, Sheila | - |
| dc.contributor.author | Lapenna, Antonio | - |
| dc.contributor.author | Lang, Pierre-Olivier | - |
| dc.contributor.author | Aspinall, Richard | - |
| dc.date.accessioned | 2014-05-23T04:00:48Z | |
| dc.date.available | 2014-05-23T04:00:48Z | |
| dc.date.issued | 2012-12-31T00:00:00Z | - |
| dc.description.abstract | Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have pro-duced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older indi-viduals are now physically more active than their forebears and travel more widely. This provides a greater opportunity for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater de-cline in their immune response than others. In this review we have sought to consider who are the ‘at risk' individuals, how they might best be treated and when. | en_UK |
| dc.identifier.citation | Govind S, Lapenna A, Lang PO, Aspinall R. Immunotherapy of immunosenesence; who, how and when? Open Longevity Science, 2012, 6, pp56-63. | |
| dc.identifier.issn | 1876-326X | - |
| dc.identifier.uri | http://dx.doi.org/10.2174/1876326X01206010056 | - |
| dc.identifier.uri | http://dspace.lib.cranfield.ac.uk/handle/1826/8476 | |
| dc.publisher | Bentham open | en_UK |
| dc.title | Immunotherapy of immunosenesence; who, how and when? | en_UK |
| dc.type | Article | - |